RxDoctor Payments DataLook up a doctor →

Christopher Daniels, MD

Interventional Cardiology · Thomasville, GANPI 1952519670

Payments from drug & device makers

$414,486in general payments, 2019–2025

Across 749 payments — averaging $553.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$172K
  • Johnson & Johnson$85K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$50K
  • Merck$33K
  • Boehringer Ingelheim International GmbH$32K
  • Angiodynamics, Inc.$13K
  • plus $32K from 34 others

What the payments were for

  • Speaking & faculty fees$79,33266%
  • Travel & lodging$11,2309%
  • Food & beverage$17,55915%
  • Education$2130%
  • Other$12,15010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$414,486 in reported general payments places this provider in the 90th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$189,890
Medicare patients
1,396
Services billed
2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis72$1,584,144
EliquisApixaban605$470,442
EntrestoSacubitril/Valsartan297$220,787
FarxigaDapagliflozin Propanediol280$196,404
XareltoRivaroxaban246$177,483
Repatha SureclickEvolocumab159$112,409
BrilintaTicagrelor155$97,638
JardianceEmpagliflozin108$89,186
Ranolazine ErRanolazine468$31,139
MultaqDronedarone Hcl18$21,431
Metoprolol Succinate1,156$12,734
VascepaIcosapent Ethyl31$11,372
CorlanorIvabradine Hcl13$10,321
EdarbiAzilsartan Medoxomil20$8,567
Atorvastatin Calcium910$7,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$408$2,054,586677 claims
AstraZenecaFarxiga, Brilinta$1,040$294,042435 claims
NovartisEntresto$171,645$220,787297 claims
Johnson & JohnsonXarelto$84,714$177,483246 claims
Boehringer IngelheimJardiance$270$89,186108 claims
Sanofi-aventis U.S. LLCMultaq$128$21,43118 claims
AmgenCorlanor$427$10,32113 claims
Arbor Pharmaceuticals, Inc.Edarbi$60$8,56720 claims
Kowa Pharmaceuticals America, Inc.Livalo$43$5,53512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →